What is the 13F Pro Quality Score for SUPN?

13F Pro ranks SUPERNUS PHARMACEUTICALS, INC. (SUPN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SUPN's current score at https://13fpro.ai/research/SUPN (free sign-up required for the full ranking).

Where does 13F Pro source SUPN data?

All SUPERNUS PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. SUPERNUS PHARMACEUTICALS, INC. files with the SEC under CIK 1356576. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SUPN in?

SUPERNUS PHARMACEUTICALS, INC. (SUPN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SUPN research updated on 13F Pro?

SUPN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SUPERNUS PHARMACEUTICALS, INC.(SUPN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1356576 SUPN stock profile & AI dashboard →

13F Pro Quality Score

45.3/100

Rank #1,726 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

66.3/100

Profitability

22.4/100

Balance Sheet

28.5/100

Earnings Quality

30.0/100

Free Cash Flow

69.7/100

Institutional Flow

70.7/100

Revenue Scale

42.8/100

Dilution Risk

27.2/100

SUPN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SUPERNUS PHARMACEUTICALS, INC. (SUPN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SUPN at 45.3/100 on a 32-signal composite quality model, placing it at rank #1,726 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (22.4) and balance sheet strength (28.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), SUPERNUS PHARMACEUTICALS, INC. reports quarterly revenue of $207.7M, net income of $-2.3M, an operating margin of -4.0%. Top institutional holders of SUPN by reported 13-F value include BlackRock,, MILLENNIUM MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. SUPN trades on the Nasdaq exchange and files with the SEC under CIK 1356576. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SUPN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SUPERNUS PHARMACEUTICALS, INC. directly from SEC EDGAR. SUPERNUS PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 8 and 73 since 2021, currently 45.3 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about SUPERNUS PHARMACEUTICALS, INC.

Quirks, history, and lore behind SUPN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · listed on Nasdaq · headquartered in Maryland · focused on central nervous system disorders.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars — a small-cap player punching in a very specialized lane, with most sales coming from just a handful of CNS drugs.
3
The History
Founded in the early 2000s, it built its commercial foundation around treatments for epilepsy, a condition that affects roughly 3.4 million Americans yet attracts far fewer drugmakers than, say, diabetes.
4
The Secret
Its pipeline has quietly expanded beyond seizures into ADHD and migraine, meaning it is essentially betting that neurologists will keep it on speed dial for multiple conditions at once.
5
The Lore
Its approved epilepsy drugs include Oxtellar XR and Trokendi XR — extended-release reformulations that turned older generic molecules into branded, patent-protected revenue engines.
6
The Giveaway
A Rockville, MD pharma focused on neurology and psychiatry, trading under a ticker that is basically just a squished version of its own name — SUPN.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$207.7M

Net Income

Q1 2026

$-2.3M

Free Cash Flow

Q1 2026

$66.5M

Operating Margin

Q1 2026

-4.0%

ROIC

Q1 2026

-0.8%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+8.6% YoY

$719.0MFY 2025

FY21 $579.8MFY23 $607.5MFY24 $661.8MFY25 $719.0M

Net Income

-152.2% YoY

$-38.5MFY 2025

FY21 $53.4MFY23 $1.3MFY24 $73.9MFY25 $-38.5M

Operating Income

-176.3% YoY

$-62.3MFY 2025

FY21 $86.0MFY23 $-5.3MFY24 $81.7MFY25 $-62.3M

EPS (Diluted)

-151.5% YoY

$-0.68FY 2025

FY21 $0.98FY23 $0.02FY24 $1.32FY25 $-0.68

Total Assets

+6.2% YoY

$1.45BFY 2025

FY21 $1.69BFY23 $1.28BFY24 $1.37BFY25 $1.45B

Total Debt

—FY 2025

FY21 $379.3MFY23 —FY24 —FY25 —

Op. Cash Flow

-72.5% YoY

$47.3MFY 2025

FY21 $127.1MFY23 $111.1MFY24 $172.0MFY25 $47.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$719.0M +8.6%	$661.8M +8.9%	$607.5M +4.8%	$579.8M +11.4%	$520.4M +32.5%	$392.8M
Net Income	$-38.5M -152.2%	$73.9M +5515.5%	$1.3M -97.5%	$53.4M -57.9%	$127.0M +12.3%	$113.1M
Operating Income	$-62.3M -176.3%	$81.7M +1649.9%	$-5.3M -106.1%	$86.0M -50.5%	$173.7M +16.9%	$148.6M
EPS (Diluted)	$-0.68 -151.5%	$1.32 +6500.0%	$0.02 -98.0%	$0.98 -58.5%	$2.36 +12.4%	$2.10
Total Assets	$1.45B +6.2%	$1.37B +7.1%	$1.28B -24.4%	$1.69B +12.3%	$1.50B +29.6%	$1.16B
Total Debt	—	—	—	$379.3M	—	—
Operating Cash Flow	$47.3M -72.5%	$172.0M +54.8%	$111.1M -12.6%	$127.1M -8.1%	$138.4M -3.3%	$143.1M

AI Insight: SUPN Financial Trends

Revenue grew 39% year-over-year to $208M in Q1 2026, but profitability remains inconsistent with volatile quarterly swings between losses and gains.

• Revenue accelerated from $150M in Q1 2025 to $208M in Q1 2026, representing 39% year-over-year growth.

• Operating cash flow surged from -$62M in Q3 2025 to $67M in Q1 2026, marking strong sequential improvement.

• Net income volatility persisted with losses in 4 of the last 6 quarters despite revenue growth.

⚠ Operating margins turned deeply negative at -31% in Q3 2025 before recovering, signaling potential cost control challenges.

⚠ Cash flow generation remains erratic, swinging from -$62M to +$67M across recent quarters.

AI Insight: SUPN Ratio Trends

Supernus Pharmaceuticals shows severe profitability deterioration with operating margin plunging from 23.2% in Q3 2024 to -4.0% in Q1 2026.

• Operating margin collapsed from 23.2% in Q3 2024 to -4.0% in Q1 2026, spanning eight quarters of decline.

• ROIC turned deeply negative, falling from 16.2% in Q3 2024 to -3.1% in Q1 2026.

• Net profit margin swung from 21.9% in Q3 2024 to -1.1% in Q1 2026.

⚠ Q3 2025 showed particularly severe deterioration with -31.4% operating margin and -22.9% ROIC.

⚠ Sequential improvement from Q3 2025 lows suggests potential stabilization, though still negative profitability.

Get alerted when SUPN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SUPERNUS PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SUPN

BlackRock, Inc.
$454.7M8,797,254 sh
MILLENNIUM MANAGEMENT LLC
$171.4M3,315,973 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$167.4M3,238,693 sh
VANGUARD CAPITAL MANAGEMENT LLC
$127.5M2,467,215 sh
DIMENSIONAL FUND ADVISORS LP
$119.2M2,307,030 sh
STATE STREET CORP
$118.3M2,288,127 sh
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$105.3M2,037,202 sh
ARMISTICE CAPITAL, LLC
$98.0M1,895,347 sh
RENAISSANCE TECHNOLOGIES LLC
$88.1M1,705,222 sh
GEODE CAPITAL MANAGEMENT, LLC
$83.9M1,623,514 sh

Fund	Value	Shares
BlackRock, Inc.	$454.7M	8,797,254
MILLENNIUM MANAGEMENT LLC	$171.4M	3,315,973
VANGUARD PORTFOLIO MANAGEMENT LLC	$167.4M	3,238,693
VANGUARD CAPITAL MANAGEMENT LLC	$127.5M	2,467,215
DIMENSIONAL FUND ADVISORS LP	$119.2M	2,307,030
STATE STREET CORP	$118.3M	2,288,127
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.	$105.3M	2,037,202
ARMISTICE CAPITAL, LLC	$98.0M	1,895,347
RENAISSANCE TECHNOLOGIES LLC	$88.1M	1,705,222
GEODE CAPITAL MANAGEMENT, LLC	$83.9M	1,623,514

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SUPN on your watchlist

Track score changes the day SUPERNUS PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SUPN a good stock to buy?

13F Pro's AI-powered analysis of SUPERNUS PHARMACEUTICALS, INC. (SUPN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SUPN are available on the SUPN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SUPN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SUPN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SUPERNUS PHARMACEUTICALS, INC.'s investment landscape.